Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Dec 24, 2020 4:01pm
182 Views
Post# 32181583

RE:RE:RE:RE:RE:RE:Soon

RE:RE:RE:RE:RE:RE:SoonKhouri sits on the board and is BusDevl  of Knight.....
MrMugsy wrote:
bringon10bagger wrote: Time for a little back scratching....Khouri is in the know?.
MrMugsy wrote:
Pandora wrote:
I see Knight Therapeutics has just issued a shelf prospectus for $360 million in share issue.
No idea what their intention is but they do mention the word acquisition. Personally I would not like to see Knight taking a bigger interest in Antibe. Hopefully Goodman is looking elsewhere.


I'm sure he's looking elsewhere too ... but ... he really should be trying to get the Latin American licenses to OTENA.  Maybe even Australia and New Zealand while he's at it.

I don't think he's interested in any other regions.  IMO.

 


What do you mean Bringon10 ?


<< Previous
Bullboard Posts
Next >>